Tibsovo Gets A Win In AML Following Servier Takeover

 
• By Alaric DeArment
  
Acute myeloid leukemia a 3d-Render
Servier announced results from the Phase III AGILE study of Tibsovo in IDH1-mutant AML • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D